Assesses Aβ1-42 detection in plasma, suggesting advances in Alzheimer’s diagnosis.
. The assay exhibited excellent specificity, with negligible cross-reactivity (<0.5%) to other amyloid isoforms, high precision indicated by coefficients of variation below 8%, and robust reagent stability under both accelerated and onboard conditions. Analysis of clinical samples demonstrated strong correlation (Spearman's ρ = 0.983) and minimal bias compared to a commercial reference method, confirming the assay's reliability. Collectively, this study successfully expanded the application of the Ficoll400-SA signal amplification carrier from enzymatic chemiluminescence assays to the AE direct chemiluminescence platform. Moreover, these findings validate the Ficoll400-SA platform as a versatile, highly sensitive, and automatable approach for detecting low-abundance biomarkers, with significant potential to advance the early diagnosis of Alzheimer's disease and biomarker research.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: